PA41-BMD: Clinical Chemistry Summary

DTTID: 108-020-007-000-8
Study Number: 108020007
Study Type: 5-Day Toxicity
Species/Strain: Mouse/B6D2F1/Crl

Test Compound: 1,2-Dichlorobenzene
CAS Number: 95-50-1
DTXSID: DTXSID6020430

Date: 20 Jun 2025
Time: 1:29:00 PM

Female Clinical Chemistry Data and BMD Values

	Treatment Groups (ppm) & BMD Values (ppm)							
	0	1	10	30	100	250	BMD_{1Std}	$BMDL_{1Std}$
Alanine Aminotransferase (IU/L)	58.9 ± 11.8[8]**	102.8 ± 45.6[4]	40.0 ± 2.0[2]	78.3 ± 12.2[3]	84.2 ± 17.3[5]	248.6 ± 34.2[7]**	157.8	108.9
Alkaline Phosphatase (IU/L)	191.5 ± 8.1[8]**	234.8 ± 9.7[4]	159.5 ± 26.5[2]	175.7 ± 11.9[3]	129.2 ± 5.3[5]**	109.4 ± 3.1[7]**	33.4	10.9
Cholesterol (mg/dL)	115.8 ± 4.9[5]**	126.5 ± 15.5[2]	129.0 ± 13.0[2]	133.0[1]	141.0[1]	194.3 ± 10.3[4]**	NVM	NVM
Sorbitol Dehydrogenase (IU/L)	25.6 ± 1.1[7]**	28.0 ± 0.1[2]	28.9 ± 4.4[2]	22.0 ± 5.5[3]	40.9 ± 6.7[4]**	108.6 ± 7.0[7]**	93.0	56.8

Values given as mean ± SEM [N].
Data with sample size of 1 in the treatment group were included in trend test, but excluded from the multiple comparisons tests.
Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.
Statistical significance for the control group indicates a significant trend test.
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.
* Statistically significant at $p <= 0.05$
** Statistically significant at $p <= 0.01$
Clinical chemistry data not reported were removed as an outlier, or due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.
BMD_{1Std} and $BMDL_{1Std}$: Benchmark response (BMR) set at 1 standard deviation from the mean.
NVM = no viable model

** END OF REPORT **